AbbVie posted higher fourth-quarter revenue on the back of growth from its immunology portfolio, led by arthritis and Crohn’s disease drugs Skyrizi and Rinvoq.
Source link
AbbVie Revenue Rises on Immunology Growth
Date:
More like thisRelated
A Rocket Supply Crunch Is Making It Harder to Hitch a Ride to Space
There’s a rush to secure flights as SpaceX winds...
Week 2 impact on the NFC: Caleb Williams, Jayden Daniels hurt
Bill BarnwellSep 21, 2026, 08:10 AM ETCloseBill Barnwell is...
New York Giants axson Dart and Malik Nabers against the Rams
Giants QB Jaxson Dart exits with knee injury and...